Excyte Biopharma Ltd

This early-stage study tests a new medicine, YKST02, in about 70 people whose multiple myeloma has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and find the right dose, while also looking for signs that it can control t…

This study tests a new drug, YK012, in 46 people with B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The main goals are to check the drug's safety, find the best dose, and see if it can shrink or control the cancer. Participants must have CD19-positive B-ALL…

This study tests a new drug, YK012, in about 189 adults with moderate to severe systemic lupus erythematosus (SLE). The goal is to see if it is safe and can help control the disease. Participants will receive the drug and be monitored for side effects and how well it works. This …

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check the drug's safety and how the body processes it. Researchers will also look for early signs that the drug mi…

This early-phase study tests a new drug called YK012 in 48 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants will receiv…